ArticleFrontiers in pharmacology2021

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting.

Zhe Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.